Company intelligence / Profile preview

CrossingBridge Advisors, LLC

Rye Brook, New York, United States

Ownership: Private
Employees: ~15
Development stage: Commercial

Overview

Not a clinical or healthcare company; focuses on investment management strategies including ultra-short duration, low duration high yield, responsible credit, and SPACs

Industry: Investors

Drug pipeline

1 asset

cannabis

Commercial

Indications: Pain, Epilepsy, Amyotrophic lateral sclerosis, Multiple sclerosis, Cancer, Post-traumatic stress disorder, Crohn's disease, Colitis, Inflammatory bowel disease

Partnerships

NCI Advisory A/S strategic partnership in 2024

Beyond the preview

Go deeper on CrossingBridge Advisors, LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CrossingBridge Advisors, LLC.

Explore the full profile